MOAB VX15/2503
MOAB VX15/2503 Uses, Dosage, Side Effects, Food Interaction and all others data.
MOAB VX15/2503 is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
| Trade Name | MOAB VX15/2503 |
| Generic | Pepinemab |
| Pepinemab Other Names | MOAB VX15/2503, Pepinemab, VX15/2503 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here MOAB VX15/2503
